MapLight Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, MapLight Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
MapLight Therapeutics: 5 sponsored US clinical trials, 4 recruiting.
MapLight Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Psychosis Associated With Alzheimer's Disease, with 1 trials.
Upper-quartile sponsor footprint
MapLight Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
Therapeutic Areas
What is open in the MapLight Therapeutics pipeline
4 recruiting of 5 indexed (80% open).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Psychosis Associated With Alzheimer's Disease (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MapLight Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 80% open enrollment, not the therapeutic-area sidebar.
MapLight Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 80% open enrollment (± trial volume)
- Alpha Tau Medical · 80% recruiting · 5 trials
- Buck Institute for Research on Aging · 80% recruiting · 5 trials
- IDEAYA Biosciences · 80% recruiting · 10 trials
- Mirador Therapeutics · 80% recruiting · 5 trials
Related
What to do with this MapLight Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of MapLight Therapeutics or any single study.
- 4 of MapLight Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Psychosis Associated With Alzheimer's Disease is the condition MapLight Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Psychosis Associated With Alzheimer's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. MapLight Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.